Cargando…
Effectiveness of proprotein convertase subtilisin/kexin‐9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic
BACKGROUND: Lipoprotein(a) (Lp[a]) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin‐9 monoclonal antibodies (PCSK9mAbs) can lower Lp(a) levels in clinical trials, but their effects in patients with elevated Lp(a) in clinical practice...
Autores principales: | Chakraborty, Anindita, Pang, Jing, Chan, Dick C., Barnett, Wendy, Woodward, Ann Marie, Vorster, Mary, Watts, Gerald F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207967/ https://www.ncbi.nlm.nih.gov/pubmed/33955565 http://dx.doi.org/10.1002/clc.23607 |
Ejemplares similares
-
Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015) -
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
por: Chan, Dick C., et al.
Publicado: (2018) -
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
por: Jang, Hyun-Duk, et al.
Publicado: (2020) -
The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods
por: Canclini, Laura, et al.
Publicado: (2021) -
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
por: Romagnuolo, Rocco, et al.
Publicado: (2017)